Inducing antiretroviral therapy (ART)-free virological control is a critical step toward a human
immunodeficiency virus type 1 (HIV-1) cure. In this phase 2a, placebo-controlled, double …

Despite long-term antiretroviral therapy (ART), HIV-1 persists within a reservoir of CD4+ T
cells that contribute to viral rebound if treatment is interrupted. Identifying the cellular …

Increasing evidence suggests that durable drug-free control of HIV-1 replication is enabled
by effective cellular immune responses that may induce an attenuated viral reservoir …

Curing HIV infection will require the elimination of a reservoir of infected CD4+ T cells that
persists despite HIV-specific cytotoxic T cell (CTL) responses. Although viral latency is a …

Background. Treatment with latency reversing agents (LRAs) enhances human
immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest …

HIV cannot be cured by current antiretroviral therapy (ART) because it persists in a
transcriptionally silent form in long-lived CD4+ cells. Leading efforts to develop a functional …

Introduction The main barrier to finding a cure against HIV is the latent HIV reservoir, which
persists in people living with HIV (PLWH) despite antiretroviral treatment (ART). Here, we …

During antiretroviral therapy (ART), human immunodeficiency virus type 1 (HIV-1) persists
as a latent reservoir in CD4+ T cell subsets in central memory (TCM), transitional memory …

ABSTRACT A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure
is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is …

Eradication of the HIV-1 latent reservoir represents the current paradigm to developing a
cure for AIDS. HIV-1 has evolved multiple mechanisms to evade CD8 T cell responses …